Lorvotuzumab mertansine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lorvotuzumab mertansine
Accession Number
DB12089
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
IMGN901
Categories
UNII
0IVD6ASY0W
CAS number
1008106-64-6

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Lorvotuzumab mertansine.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Lorvotuzumab mertansine.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Lorvotuzumab mertansine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Lorvotuzumab mertansine.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Lorvotuzumab mertansine.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Lorvotuzumab mertansine.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Lorvotuzumab mertansine.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Lorvotuzumab mertansine.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Lorvotuzumab mertansine.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Lorvotuzumab mertansine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911280
Wikipedia
Lorvotuzumab_mertansine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCancer of the Ovary / Lung Cancer Small Cell Lung Cancer (SCLC) / Neuroendocrine Carcinoma of the Skin1
1CompletedTreatmentMultiple Myeloma (MM)2
1, 2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Active Not RecruitingTreatmentPleuropulmonary Blastoma / Recurrent Malignant Peripheral Nerve Sheath Tumor / Recurrent Neuroblastoma / Recurrent Rhabdomyosarcoma / Recurrent Synovial Sarcoma / Wilms' tumor1
2CompletedTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. [PubMed:11020135]

Drug created on October 20, 2016 15:19 / Updated on June 04, 2019 07:31